- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04559230
Sacituzumab Govitecan in Recurrent Glioblastoma
March 11, 2024 updated by: William Kelly, The University of Texas Health Science Center at San Antonio
A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
This is an open-label single arm study.
All patients will receive the investigational agent.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Epp Goodwin
- Phone Number: 210-450-1000
- Email: goodwine@uthscsa.edu
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland Clinic Taussig Cancer Center
-
Contact:
- Felicia Williams
-
Principal Investigator:
- Christine Cordova, MD
-
-
Texas
-
Dallas, Texas, United States, 75251
- Recruiting
- Texas Oncology
-
Contact:
- Kelly Juniper
-
Principal Investigator:
- Brian Valliant, MD
-
San Antonio, Texas, United States, 78229
- Recruiting
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
-
Contact:
- Epp Goodwin
- Email: goodwine@uthscsa.edu
-
Contact:
- William Kelly, MD
- Phone Number: 210-450-1000
- Email: kellyw@uthscsa.edu
-
Principal Investigator:
- William Kelly, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At least 18 years of age
- Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
- Histologically confirmed IDH wild-type (de novo) GBM
- Progression following standard combined modality treatment with radiation and temozolomide chemotherapy if O6-Methylguanine-DNA Methyltransferase (MGMT) methylated; prior temozolomide is not required for MGMT unmethylated, but patient must have received standard doses of radiation. Inclusion of additional investigational therapy with standard therapy is not exclusionary. No additional lines of therapy.
- Patients may have had been operated for recurrence, but if operated must have had surgery a minimum of 2 weeks prior to enrollment and have an MRI completed within 48 hours following surgery.
- No radiotherapy within the three months prior to the diagnosis of progression.
- Willingness to forego tumor treatment field (Optune) therapy during participation in the study.
- Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.
- Recovered from toxicities of prior therapy to grade 0 or 1, except for neuropathy (≤Grade 2) and alopecia.
- ECOG performance status ≤ 2
- Life expectancy of at least 6 months
Acceptable liver function:
- Bilirubin ≤ 1.5 times upper limit of normal
- AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN);
Acceptable renal function:
a. creatinine clearance ≥30 mL/minute according to the Cockcroft and Gault formula
Acceptable hematologic status (without hematologic support):
- ANC ≥1500 cells/uL
- Platelet count ≥100,000/uL
- Hemoglobin ≥9.0 g/dL
- All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose
- Availability of biological material for central review and biomarker evaluation
Exclusion Criteria:
- Prior treatment with bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling inhibitors
- The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.
- The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.
- The subject is unable to undergo MRI scan (eg, has pacemaker).
- The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).
- The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade ≤ 1 from AEs (except alopecia, anemia and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other medications that were administered prior to study drug.
- The subject is pregnant or breast-feeding.
The subject has serious intercurrent illness, such as:
- hypertension (two or more blood pressure [BP] readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment
- non-healing wound, ulcer, or bone fracture
- significant cardiac arrhythmias
- untreated hypothyroidism
- unhealed rectal or peri-rectal abscess
- uncontrolled active infection
- symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug any history of cardiac arrhythmia or heart block
- stroke or transient ischemic attack within 6 months
The subject has received any of the following prior anticancer therapy:
- Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed
- Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior first dose of study drug
- Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug
- Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
- Prior treatment with carmustine wafers
- Patients with radiographically apparent leptomeningeal involvement are excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sacituzumab govitecan
Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
|
Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated.
Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 6 months
|
A single-arm two-stage Phase II Bayesian adaptive study of Sacituzumab Govitecan will be carried out in the expansion phase based on progression free survival at 6 months with unfavorable and favorable probabilities of 0.17 and 0.34, respectively.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: William Kelly, MD, Mays Cancer Center, UT Health San Antonio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
September 16, 2020
First Submitted That Met QC Criteria
September 16, 2020
First Posted (Actual)
September 22, 2020
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Immunologic Factors
- Immunoconjugates
- Sacituzumab govitecan
Other Study ID Numbers
- CTMS# 20-0102
- HSC20200576X (Other Identifier: UT Health Science Center San Antonio)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Sacituzumab Govitecan
-
Icahn School of Medicine at Mount SinaiNot yet recruitingOvarian Cancer | Malignant Neoplasm of UterusUnited States
-
Gilead SciencesApproved for marketingMetastatic Triple-Negative Breast Carcinoma
-
Fudan UniversityRecruiting
-
SOLTI Breast Cancer Research GroupNot yet recruitingBreast Cancer Stage IVSpain
-
The University of Texas Health Science Center at...Gilead SciencesActive, not recruiting
-
M.D. Anderson Cancer CenterGilead SciencesRecruitingSalivary Gland Cancers | GlandUnited States
-
Georgetown UniversityGilead SciencesNot yet recruitingThymic Carcinoma | ThymomaUnited States
-
University Hospital HeidelbergNot yet recruitingMetastatic Colorectal CancerGermany
-
Yale UniversityGilead SciencesRecruitingEndometrial CarcinomaUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Gilead SciencesRecruiting